AIM ImmunoTech Regains Compliance with NYSE American Listing Standards

On June 15, 2026, AIM ImmunoTech Inc. announced that it received a letter from NYSE Regulation on June 12, 2026, confirming the company has regained compliance with the continued listing standards of the NYSE American LLC. The company successfully resolved previously identified deficiencies under Section 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide related to stockholders' equity requirements. To achieve compliance, AIM ImmunoTech executed several financing transactions in May and June 2026, including a warrant exercise inducement agreement and two concurrent private placements of common stock and warrants. These actions generated aggregate gross proceeds of approximately $8.5 million, bringing the company's stockholders' equity above the $6.0 million minimum requirement. As a result, the 'below compliance' (.BC) indicator will be removed from the company's trading symbol, and AIM will be removed from the exchange's list of noncompliant issuers. The company remains subject to standard continued listing monitoring procedures.